Universitätsklinik für Neurologie Christian-Doppler-Klinik, Ignaz-Harrer-Straße 79, A-5020 Salzburg Vorstand: Prim. Univ. Prof. Dr. Mag. Eugen Trinka Tel: +43(0)662 4483-0, Fax: +43(0)662 4483-3004, Email: [email protected] Studiengruppe: MULTIPLE SKLEROSE Studiengruppenleiter: OA Priv. Doz. DDr. Johann Sellner Tel. +43-662-4483-56089, FAX: +43-662-4483-3076 Email: [email protected] Studienteam: Daniela Sinadinoska, Leitung Studienzentrale Neurologie, Tel: +43-662-4483-3120, Email: [email protected]; [email protected] FA Dr. Peter Wipfler, Co-Investigator, Tel: +43-662-4483-56014, Email: [email protected] FA Dr. Georg Pilz, Co-Investigator, Tel: +43-662-4483-56058, Email: [email protected] DDr. Ljiljana Milinovic, Study-Coordinator, Tel: +43-662-4483-3120, Email: [email protected]; [email protected] Patientenpopulation: ca. 2000 ambulante Patienten/Jahr Studie Phase Sponsor Patienten gescreent Patienten in Behandlung PROTEC IV Quintiles/ BiogenIdec 10 9 ORATORIO: A Phase III, multicentre, randomized, parallel-group, double blinded, placebo controlled study to evaluate the efficacy and safety of ocrelizumab in adults with Primary Progressive Multiple Sclerosis ORATORIO III Roche 5 4 GAM 27: Active-controlled phase IIb study to investigate the ability of the HAP score to predict responders to Octagam 5% in patients with early relapsing multiple sclerosis GAM 27 IIb Octapharma 2 1 CONFIDENCE: Assessment of COgnitioN, Fatigue, Depression, anxiety, adherENCE in Relapsing Remitting Multiple Sclerosis patients treated with Rebif in real life settings CONFIDENCE IV Merck Serono 2 2 CFTY720: A single arm, open-label, multicenter study evaluating the longterm safety and tolerability of 0.5 mg fingolimod (FTY720) administered orally once daily in patients with relapsing forms of multiple sclerosis CFTY720 IIIb Novartis 5 1 Klinische Studien aktuell: PROTEC: A Multicenter, Open-Label Study Evaluating the Effectiveness of Oral Tecfidera™ (Dimethyl Fumarate) on MS Disease Activity and Patient-Reported Outcomes in Subjects with Relapsing-Remitting Multiple Sclerosis in the Real-World Setting Klinische Studien in Vorbereitung: BETAEVAL - The New BETACONNECT® Auto-injector: Adherence and EVALuation of MS Patients Treated With Betaferon® Bayer, Phase IV TECFIDERA - A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy of BG00012 in Reducing Disability Progression in Subjects With Secondary Progressive Multiple Sclerosis Biogen Idec/Quintiles, Phase III PASS OBS13434 - A prospective, multicenter, observational, post-authorization safety study (PASS) to evaluate the long term safety profile of LEMTRADA® (alemtuzumab) treatment in patients with relapsing forms of multiple sclerosis (RMS) Sanofi Aventis, Phase IV STAMINA - Stem cell Therapy for Adult Multiple sclerosis patients in Austria: Phase 1/2 Clinical Trial with autologous Mesenchymal Stem Cells(MSCs) for the therapy of multiple sclerosis Akademische Studie (Sponsor: Neurologische Klinik) CRCS Forum Klinische Studien Salzburg 04.11.2014
© Copyright 2024 ExpyDoc
